Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Seroxo Limited currently manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 2 distinct examiners across 2 distinct art units. HILL, MYRON G is the busiest examiner, with 1 pending office action.
The 2 pending office actions are evenly split between the 2 distinct examiners. HILL, MYRON G is responsible for one of these actions, representing half of the active portfolio. The involvement of 2 distinct art units suggests that Seroxo Limited is pursuing different technical aspects within the Biotechnology & Pharmaceuticals sector.
Practitioners must navigate two separate examination environments. With 2 distinct examiners and 2 distinct art units, the company may experience different timelines and feedback. The strategy involves managing these 2 pending office actions independently to achieve the company's patent goals in the Biotechnology & Pharmaceuticals field. This split workload requires attention to the specific procedural nuances of each distinct art unit involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HILL, MYRON G | 1 | 66.1% | +20.7% |
| ALABI, OYELEYE A | 1 | 83.9% | +23.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275343 | MONITORING COVID-19 PROGRESSION AND TREATMENT | HILL, MYRON G | — |
| 18268792 | METHOD FOR DIAGNOSING AND MONITORING SEPSIS | ALABI, OYELEYE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275343 | MONITORING COVID-19 PROGRESSION AND TREATMENT | HILL, MYRON G | — |
| 18268792 | METHOD FOR DIAGNOSING AND MONITORING SEPSIS | ALABI, OYELEYE A | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| 1797 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18275343 | MONITORING COVID-19 PROGRESSION AND TREATMENT | HILL, MYRON G | 1672 | §102§103§112 | Non-Final OA | — | Pending | Aug 01, 2023 |
| 18268792 | METHOD FOR DIAGNOSING AND MONITORING SEPSIS | ALABI, OYELEYE A | 1797 | §101§103 | Non-Final OA | — | Pending | Jun 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSeroxo Limited has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Myron G Hill has the most, with 1 of Seroxo Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
